Enzalutamide (Xtandi®)


Indications for Prior Authorization:

  • Metastatic castration-resistant prostate cancer

Patients must meet the following criteria for the indication(s) above:

  • Must have prior treatment with docetaxel
  • Must have castration resistant prostate cancer (progression after either GnRH therapy or bilateral orchiectomy)

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P&T Committee:

  • All non-FDA approved uses not listed in the approved indications
  • Drug is not indicated for use in women


  • 160 mg orally once daily
  • Avoid co-administration with a strong CYP2C8 inhibitor
  • If drug cannot be avoided reduce dose to 80 mg PO daily


  • Enzalutamide is a strong enzyme inducer, CYP3A4, CYP2C9, CYP2C19. Will reduce plasma concentrations of drug such as warfarin and omeprazole.
  • Seizure risk 0.9% in clinical trial


6 months


Last review date: October 22, 2018

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar